Nurix Therapeutics Inc
NRIX
Company Profile
Business description
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Contact
1600 Sierra Point Parkway
BrisbaneCA94005
USAT: +1 415 660-5320
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 November 2026
Employees
357
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
Investors are raising concerns about the future of telecommunication connectivity in Australia.
stocks
Chart of the Week: This ASX top pick might be overlooked
ASX top pick remains cheap as investor concerns around wage costs might be overdone.
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.90 | 50.20 | 0.55% |
| CAC 40 | 8,430.79 | 16.48 | -0.20% |
| DAX 40 | 24,934.67 | 24.26 | 0.10% |
| Dow JONES (US) | 51,492.55 | 507.12 | -0.98% |
| FTSE 100 | 10,508.61 | 14.40 | 0.14% |
| HKSE | 24,312.16 | 181.79 | -0.74% |
| NASDAQ | 26,021.66 | 354.69 | -1.34% |
| Nikkei 225 | 70,535.18 | 632.93 | 0.91% |
| NZX 50 Index | 13,366.84 | 26.14 | -0.20% |
| S&P 500 | 7,420.10 | 91.25 | -1.21% |
| S&P/ASX 200 | 8,948.70 | 47.90 | 0.54% |
| SSE Composite Index | 4,108.08 | 16.18 | 0.40% |